FDA has accepted a license for complementary biological products from Mercadon Gardasil 9

recently, the U.SPharmaceutical sandannounced that the U.SFood andDrug(
FDA) has accepted a supplementary biologics license (sBLA) for the Gardasil 9 (Plus, 9-price recombinant human papillomavirus vaccine) and granted priority review eligibility, its prescription drug user charge spending law (PDUFA) date of October 6, 2018the sBLA aims to seek approval to expand Gardasil 9's age-adaptation for men and women aged 27-45 to prevent certain cancers and diseases caused by the nine hpv types covered by the vaccineabout Gardasil 9the most common type of HPV in the world than any listed HPV vaccine, which, after type 16 and 18 HPV, is the most common type of HPV caused worldwidein the United States, Gardasil 9 is suitable for women aged 9-26 to prevent 7 types of high-risk HPV (16, 18, 31, 33, 45, 52, 58) caused by cervical, vulva, vaginal, cancer, and prevent syltosis caused by 2 types of low-risk HPV (6, 11)in addition,, Gardasil 9 is also suitable for men aged 9-26 to prevent 7 types of high-risk HPV (16, 18, 31, 33, 45, 52, 58) caused by cancer, prevention of genital warts caused by 2 low-risk HPV (6, 11), prevention of 9 types of HPV (6, 11, 16, 18, 31, 33, 45, 52, 58) or pre-cancerous diseaseto date, Gardasil 9 has been approved for use in more than 70 countries around the world